Silence Therapeutics plc
SLNCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | -$0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -29% | 57.7% | -99.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.7% | 62.1% | 62% | 93.4% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -16,407.5% | -10,040.6% | -13,950.7% | 29.6% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -13,181.1% | -12,211.6% | -20,091.5% | 58.3% |
| EPS Diluted | -0.15 | -0.19 | -0.2 | 0.1 |
| % Growth | 21.1% | 5% | -300% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |